Publications by authors named "Aizezi Aihaiti"
Numerous studies have investigated the role of ( polymorphisms in musculoskeletal soft tissue injuries (MSTIs), yielding conflicting results. This study was designed to synthesize existing evidence and clarify the relationship between polymorphisms and MSTI susceptibility. We conducted a comprehensive literature search using PubMed, Cochrane Library, Web of Science, EMBASE, and Wanfang databases.
View Article and Find Full Text PDFObjective: Inconsistent findings existed on the correlation of collagen type V α1 (COL5A1) gene polymorphisms and musculoskeletal soft tissue injuries (MSTIs). The purpose of this study was to collect and combine the current evidences by a meta-analysis approach.
Methods: Six online databases were searched up to August, 2021.
Association between matrix metalloproteinase-3 gene polymorphisms and tendon-ligament injuries: evidence from a meta-analysis.
BMC Sports Sci Med Rehabil
February 2022
Background: Tendon-ligament injuries (TLIs), including Achilles tendinopathy, cruciate ligament injury, tennis elbow, rotator cuff injury, patellar tendinopathy, and tibial tendinopathy, are common musculoskeletal soft injuries during physical activity. Matrix metalloproteinase-3 (MMP-3) gene polymorphisms have been implicated in the etiology of TLIs in several genetic association studies with inconsistent results. The purpose of this study was to collect and synthesize the current evidences on the association of MMP-3 polymorphisms and TLIs.
View Article and Find Full Text PDFArticle Synopsis
- Previous studies suggest that microRNA-150 (miR-150) acts as a tumor suppressor in osteosarcoma by targeting IGF2BP1, but its clinical significance is not fully understood.
- The researchers analyzed the expression levels of miR-150 and IGF2BP1 in osteosarcoma tissues versus noncancerous tissues and found decreased miR-150 and increased IGF2BP1 in cancerous tissues.
- They concluded that low levels of miR-150 and high levels of IGF2BP1 are linked to worse clinical outcomes, suggesting the miR-150/IGF2BP1 axis could be a promising target for developing new treatments for osteosarcoma.